Jane Street Group LLC Acquires 166,589 Shares of Delcath Systems, Inc. (NASDAQ:DCTH)

Jane Street Group LLC lifted its position in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 1,364.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 178,797 shares of the company's stock after acquiring an additional 166,589 shares during the quarter. Jane Street Group LLC owned approximately 0.56% of Delcath Systems worth $2,153,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in DCTH. Vivo Capital LLC raised its stake in Delcath Systems by 71.4% in the fourth quarter. Vivo Capital LLC now owns 1,708,579 shares of the company's stock valued at $20,571,000 after purchasing an additional 711,574 shares in the last quarter. Gilder Gagnon Howe & Co. LLC purchased a new stake in shares of Delcath Systems during the 4th quarter valued at $7,371,000. Silverarc Capital Management LLC bought a new stake in shares of Delcath Systems during the 4th quarter worth $1,870,000. Kennedy Capital Management LLC grew its position in Delcath Systems by 89.6% in the fourth quarter. Kennedy Capital Management LLC now owns 258,782 shares of the company's stock worth $3,116,000 after acquiring an additional 122,318 shares in the last quarter. Finally, ADAR1 Capital Management LLC raised its position in Delcath Systems by 381.1% during the fourth quarter. ADAR1 Capital Management LLC now owns 149,385 shares of the company's stock valued at $1,799,000 after purchasing an additional 118,333 shares in the last quarter. Hedge funds and other institutional investors own 61.12% of the company's stock.

Delcath Systems Trading Down 0.7%

Shares of DCTH stock traded down $0.13 during mid-day trading on Tuesday, reaching $17.97. The stock had a trading volume of 404,994 shares, compared to its average volume of 368,219. The firm has a market capitalization of $625.82 million, a PE ratio of -13.31 and a beta of 0.72. Delcath Systems, Inc. has a 52-week low of $6.33 and a 52-week high of $18.21. The stock's 50-day moving average price is $12.73 and its two-hundred day moving average price is $12.82.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.07). Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. The company had revenue of $19.80 million during the quarter, compared to analysts' expectations of $16.83 million. On average, equities research analysts forecast that Delcath Systems, Inc. will post -0.79 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright boosted their price objective on shares of Delcath Systems from $22.00 to $24.00 and gave the stock a "buy" rating in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $22.75.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.